K药皮下剂型被诉专利侵权4月24日,美国生物技术公司Halozyme在新泽西州的美国地方法院对默沙东提起专利侵权诉讼。Halozyme认为,默沙东即将上市的Keytruda(可瑞达,K药)皮下剂型侵犯了Halozyme自2011年开始为保护其突破性的MDASE皮下递送技术而申请的多项专利。据悉,Halozyme的MDASE皮下递送技术利用人透明质酸酶实现药物的快速、大容量皮下注射。Halozyme...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.